MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Novacyt hails positive UK trial data for Covid-19 test

StockMarketWire.com

Paris-based diagnostics group Novacyt said encouraging interim data had been reported from an ongoing clinical trial in care homes that was assessing the accuracy of its Covid-19 test.

Queen Mary University of London had completed an interim review of the performance of the company's near-patient testing system that involved an analysis of over 4,000 samples from care home residents and staff.

The clinical accuracy of Novacyt's system was found to have greater than 99% clinical sensitivity and specificity when compared to a standard central laboratory system.

'These data demonstrate the reliability and accuracy of Novacyt's NPT system,' the company said.

'In addition, mid-nose nasal swabs were found to be effective and well tolerated compared to the more invasive nasopharyngeal swabs.'

Novacyt also announced the launch of a new product to improve the workflow efficiency of its near-patient testing COVID-19 test.

At 9:36am: (LON:NCYT) Novacyt S.A share price was 0p at 897p


Story provided by StockMarketWire.com